Cliniques universitaires St-Luc
Brussels, 1200, Belgium
NCT Number: NCT03943719
Molecular testing is a largely validated approach allowing rapid identification of positive blood cultures. However, due to its high cost and its limited information on susceptibility, it is considered as an add-on technique reserved for specific patient populations. In our study, we specifically evaluated molecular testing in a critical care setting and measured its impact on the therapeutic management of critically ill with positive blood cultures. Through the analysis of 110 positive blood culture episodes included in both pre- and post intervention period, we measured a drastic 14h-reduction of the time to administration of the optimal antimicrobial treatment with the use of the molecular approach.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Brussels, 1200, Belgium
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
Time frame: From positivity detection of positive blood culture to administration of optimal treatment (up to 48 hours)
Time in minutes
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Other
The Impact of a Rapid Molecular Identification Test on Positive Blood Cultures From Critically Ill With Bacteremia: a Pre-post Intervention Study
Acronym: SEPSIS2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02988414
Bacteremia, Bacterial Infections
Durham, North Carolina, United States
View Trial DetailsNCT01520597
Bacterial Infections, Bacterial Infections and Mycoses
Paris, France
View Trial DetailsNCT05045963
Hematologic Diseases, Hematologic Neoplasms
Houston, Texas, United States
View Trial DetailsNCT05040503
Infections, Inflammation
Dijon, France
View Trial Details